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ABSTRACT
During the last 60 years numerous significant
attempts have been made to achieve a widely
acceptable terminology and histological grad-
ing for laryngeal squamous intraepithelial
lesions. While dysplasia was included in the
pathology of the uterine cervix already in 1953,
the term dysplasia was accepted in laryngeal
pathology first after the Toronto Centennial
Conference on Laryngeal Cancer in 1974. In
1963 Kleinsasser proposed a three-tier classifi-
cation, and in 1971 Kambic and Lenart pro-
posed a four-tier classification. Since then, four
editions of the World Health Organisation
(WHO) classification have been proposed (1978,
1991, 2005 and 2017). Several terms such as
squamous intraepithelial neoplasia (SIN) and
laryngeal intraepithelial neoplasia (LIN) are
now being abandoned and replaced by squa-
mous intraepithelial lesions (SIL). The essential
This article was written by members and invitees of the
International Head and Neck Scientific Group (www.
IHNSG.com).
Digital Features To view digital features for this article
go to https://doi.org/10.6084/m9.figshare.12095979.
H. Hellquist (&)
Epigenetics and Human Disease Laboratory, Faro,
Portugal
e-mail: henrikhellquist@gmail.com
H. Hellquist
Department of Biomedical Sciences and Medicine,
Faro, Portugal
H. Hellquist
Centre of Biomedical Research (CBMR) and Algarve
Biomedical Center (ABC), Faro, Portugal
A. Ferlito
International Head and Neck Scientific Group,
Padua, Italy
A. A. Ma¨kitie
Department of Otorhinolaryngology Head and Neck
Surgery, University of Helsinki and Helsinki
University Hospital, Helsinki, Finland
L. D. R. Thompson
Department of Pathology, Southern California
Permanente Medical Group, Woodland Hills
Medical Center, Woodland Hills, CA, USA
J. A. Bishop
Department of Pathology, University of Texas
Southwestern Medical Center, Dallas, TX, USA
A. Agaimy
Institute of Pathology, University Hospital,
Friedrich-Alexander University Erlangen-Nu¨rnberg,
Erlangen, Germany
J. C. Hernandez-Prera
Department of Pathology, Moffitt Cancer Centre,
Tampa, FL, USA
D. R. Gnepp
Department of Pathology, Alpert Medical School at
Brown University, Providence, RI, USA
Adv Ther (2020) 37:2667–2677
https://doi.org/10.1007/s12325-020-01348-4
change between the 2005 and 2017 WHO
classifications is the attempt to induce a sim-
plification from a four- to a two-tier system. The
current WHO classification (2017) thus recom-
mends the use of a two-tier system with rea-
sonably clear histopathological criteria for the
two groups: low-grade and high-grade dyspla-
sia. Problems with interobserver variability
apart, subjectivities and uncertainties remain,
but to a lesser degree. Ongoing and additional
molecular studies may help to clarify underly-
ing events that will increase our understanding
and possibly can facilitate our attempts to
obtain an even better classification. The classi-
fication needs to be easier for the general
pathologist to perform and easier for the clini-
cian to interpret. These two objectives are
equally important to provide each patient the
best personalised treatment available for squa-
mous intraepithelial lesions.
Keywords: Laryngeal dysplasia; Laryngeal
precancerous lesions; Laryngeal precursor
lesions; WHO classification
Key Summary Points
For more than 60 years pathologists and
otolaryngologists worldwide have made
serious efforts to achieve a histological
grading system of squamous
intraepithelial lesions.
The 1974 Toronto Centennial Conference
on Laryngeal Cancer was an important
kick-off point.
There have now been four editions of
WHO classification proposals for these
lesions (1978, 1991, 2005 and 2017) but
uncertainties and controversies remain,
albeit to a lesser degree than before.
Several terms, such as squamous
intraepithelial neoplasia (SIN) and
laryngeal intraepithelial neoplasia (LIN),
are, after the WHO classification (2017),
slowly fading away in the developmental
process of the classification and giving
room for ‘‘squamous intraepithelial
lesions’’ (SIL).
The Ljubljana classification with its
amendment of 2014 has not gained a
wider acceptance in routine
histopathology. It has contributed
considerably to the existing WHO
suggestion of a two-tier system, i.e., low-
and high-grade lesions. Despite several
potential benefits of a two-tier system,
wide endorsement of the classification
remains to be achieved.
During the last 60 years numerous distin-
guished pathologists and otolaryngologists-
head and neck surgeons have made significant
attempts to achieve a widely acceptable termi-
nology and histological grading for laryngeal
squamous intraepithelial lesions. The prime
objective of any proposed grading system has
been to obtain a readily reproducible system
that is able to reliably predict the biological
behaviour and prognosis and thus guide
appropriate therapy. Accordingly, the grading
system should have defined morphological cri-
teria with an interobserver variability as mini-
mal as possible. The terminology in use has to
be simple or self-explaining and familiar to
clinicians for the grading system to act as a
useful guidance for clinical management. The
system should provide a reasonably accurate
prediction of the risk of recurrence, risk for
progression and development of frank malig-
nancy. As controversies and uncertainties
remain to this day, further improvement in the
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grading of squamous intraepithelial lesions,
possibly with use of new molecular techniques,
is highly desirable and of utmost importance for
the clinical management and prognosis.
Already in 1952, a long time before the term
dysplasia was acknowledged and established in
laryngeal pathology, Stout and others drew
attention to the existence of laryngeal squa-
mous cell carcinoma in situ [1–3]. Other early
studies were performed to distinguish between
various proliferative epithelial laryngeal lesions
and to assess the frequency with which they
develop into invasive carcinoma [4–6]. In 1963
Kleinsasser, an eminent European laryngologist
of the last century, proposed a three-tier classi-
fication for proliferative squamous cell lesions
that was based primarily on nuclear atypia.
Group I consisted of simple hyperplasia, group
II of restless hyperplasia and group III of carci-
noma in situ [7]. In 1971 Kambicˇ and Lenart
proposed a four-tier classification mainly based
on hyperplasia, either simple, abnormal or
atypical hyperplasia, and carcinoma in situ [8].
Neither of these two proposals gained any wider
acceptance in the Anglo-Saxon medical world,
possibly because they were published in Ger-
man and French and in clinical head and neck
journals, not pathology journals. While dys-
plasia was included in the pathology of the
uterine cervix already in 1953 [9], it took 2 more
decades before the term dysplasia was intro-
duced in laryngeal pathology at the Workshop
at the Centennial Conference on Laryngeal
Cancer held in Toronto in 1974 [10]. The
nomenclature recommended by attending
prominent pathologists and otolaryngologists
(such as Batsakis, Bauer, Fechner, Fisher, Fried-
mann and Miller, to name just a few) was in fact
rather closely consistent with that of Klein-
sasser. The 1974 proposal was further refined
over the years and constituted the foundation
for both the first (1978) and second (1991) edi-
tion of World Health Organisation (WHO) his-
tological classifications, both of which endorsed
laryngeal dysplasia [11, 12]. The second WHO
classification recognised mild, moderate and
severe dysplasia, while carcinoma in situ was
discussed separately.
The Toronto Conference in 1974 initiated
many clinicopathological studies on laryngeal
proliferative epithelial lesions in efforts to
obtain increased knowledge and create an
improved grading system. Many of the investi-
gations also included the use of different ancil-
lary techniques available at that time, such as
DNA analysis, quantitative morphometry,
immunohistochemistry and scanning electron
microscopy, among others [13–41]. The term
squamous intraepithelial neoplasia (SIN) was
used for laryngeal precursor lesions by Fried-
mann and Osborn in 1976 [13], and 10 years
later Crissman and Fu opted for intraepithelial
neoplasia of the larynx [42]. In addition, Fried-
mann and Ferlito used laryngeal intraepithelial
neoplasia (LIN). An attempt to reconcile differ-
ent schemes showed LIN I is regarded the
equivalent of mild dysplasia, LIN II of moderate
dysplasia and LIN III of severe dysplasia and
carcinoma in situ [36]. Parts of the SIN and LIN
proposals appeared in the third (2005) and
fourth (2017) editions of the WHO classifica-
tions [43, 44]. The publication in 1995 of the
Ljubljana experience by Kambicˇ and Gale was a
strong revival of the old 1971 Kambicˇ and
Lenart classification. This constituted a major
new foundation for several studies and became
known as the Ljubljana classification [40, 45].
Well before the third edition of the WHO clas-
sification an excellent review was written by
Wenig in 2002 and further updated in 2017. It
comprised not only laryngeal lesions but also
those of the entire upper respiratory tract and
pinpointed basic definitions of the terminology
and the histological and clinical differences
between severe dysplasia and carcinoma in situ.
In addition, several other important issues were
included that still, almost 20 years later, are
most appropriate and valid, although still
unsolved [46, 47]. It is noteworthy that similar
efforts undertaken for squamous precursor
lesions in other head and neck organs had cer-
tain success. The dysplasia concept of mild,
moderate and severe grading was recommended
for oral precancerous lesions and is widely used
(see Warnakulasuriya et al. for a review) [48] but
a uniform/standard histopathological termi-
nology for proliferating lesions of stratified
squamous epithelia in other head and neck
organs has not yet materialised. It is also
important to emphasise that laryngeal dysplasia
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is histologically different from uterine cervical
dysplasia because of the presence of epithelial
thickening, surface maturation/keratinisation
and dyskeratosis. The classic carcinoma in situ
with full epithelial replacement is rare in the
larynx. This phenomenon was described by
Hellquist et al. in 1982 [20], Crissman in 1982
[49], Crissman et al. in 1988 [50] and Crissman
and Zarbo in 1989 [29]. The studies in 1982 and
1989 also demonstrated that severe keratinising
dysplasia carried a risk of greater frequency of
progression to squamous cell carcinoma than
that of full thickness carcinoma in situ [20, 29].
In an attempt to clarify and reduce the con-
troversy that existed in the 1990s after the
publication of the second WHO classification,
the third WHO Blue Book on Pathology and
Genetics of Head and Neck Tumours was pub-
lished in 2005 [51]. It presented three often-
used schemes for classifying laryngeal precursor
lesions (WHO, SIN and Ljubljana). The schemes
included: (1) a five-grade dysplasia system fea-
turing squamous cell hyperplasia, mild, mod-
erate and severe dysplasia, and carcinoma
in situ; (2) a three-grade SIN featuring mild
dysplasia (basal/parabasal hyperplasia), moder-
ate and severe dysplasia (severe dysplasia and
carcinoma in situ) and (3) a four-grade Ljubl-
jana classification featuring squamous hyper-
plasia, basal/parabasal hyperplasia, atypical
hyperplasia and carcinoma in situ [44]. How-
ever, studies assessing the interobserver vari-
ability did not show superiority of any of the
three classification systems [52–54].
Problems with interobserver variability
apart, subjectivities and uncertainties remained
after the 2005 WHO recommendations. Further
studies took place to refine the exact morpho-
logical criteria for histological grading and
revise existing classifications, and more molec-
ular studies were introduced. Before an amen-
ded Ljubljana classification was proposed in
2014 [55], several updates and reviews were
undertaken [56–58]. An interesting approach
was presented in 2012 by Ferlito et al. who
placed pathological changes into two groups
based on their clinical relevance with regard to
treatment. The first group would generally not
require any additional treatment or close fol-
low-up (briefly, metaplastic, hyperplastic and
keratotic lesions) while the second group would
demand either local therapy or close follow-up
to monitor any progression to a more aggressive
pathology (briefly, dysplasia and carcinoma
in situ) [59]. This system is very attractive, as
most two-tier systems are, but they all share the
shortcoming of artificial lumping of those
lesions with moderate histological dysplasia
into either the low- or high-grade category. This
is simply true as moderately dysplastic lesions
do occur along the continuum of preneoplastic
changes. For many if not most pathologists,
albeit following recommended criteria for
architectural disturbances and cytological
atypia, moderate dysplasia is often for those
dysplastic lesions that do not fit either end of
the scale, thus falling in between. This descrip-
tion of moderate dysplasia, although not sci-
entifically attractive, and possibly not valid,
represents a useful applied approach to routine
histopathological reporting. Several prolifera-
tive laryngeal squamous lesions are reversible
and do not progress, and some are not neo-
plastic processes per se. The term precursor
lesion is used in the latest 2017 WHO classifi-
cation for dysplasia of any grade. However,
distinction among proliferation, neoplasia and/
or neoplasm is, although necessary, not always
possible or reproducible. Therefore, terms such
as laryngeal intraepithelial neoplasia (LIN),
intraepithelial neoplasia of the larynx and
squamous intraepithelial neoplasia (SIN) are not
appropriate. The term squamous intraepithelial
lesion (SIL) is much preferred, and after the
amendment of the Ljubljana classification in
2014, the term SIL became firmly established
and accepted by most as the best term for pro-
liferating intraepithelial laryngeal lesions [55].
Further studies contributing to the updates
eventually led to the new WHO classification
published in the 2017 [44, 60, 61].
The current WHO classification (2017) rec-
ommends the use of a two-grade system, fol-
lowing a trend in other organs, such as
oesophageal dysplasia and dysplasia of intesti-
nal adenomas. Reasonably clear histopatholog-
ical criteria are given for defining the two
groups: low-grade and high-grade dysplasia. If a
three-tier system is preferred, then high-grade
dysplasia and carcinoma in situ should be
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separated for management considerations [44].
For details, the interested reader should consult
Chapter 3, Tables 3.02 and 3.03, in the 2017
WHO classification (although these two
tables are not entirely in agreement) [62].
However, despite the benefits of the 2017 WHO
classification, wide endorsement of the classifi-
cation remains to be achieved. Some prefer to
state that laryngeal dysplasia is now separated
into only low- and high-grade categories [63],
whilst others have a more cautious approach
partially adopting histological criteria for a
dysplasia system compared with the 2017 WHO
classification. For example, Wenig subdivided
dysplasia into classic or non-keratinising, basal-
cell type and keratinising spinous type. He also
emphasises the importance of an increased
number of dyskeratotic cells appearing
throughout the entire epithelium as indicative
of the presence of significant dysplasia [47].
Others regard the 2017 WHO classification as a
potential source of disunity regarding the
number of grades and morphological criteria
and pointing out that the system creates diffi-
culties in providing reliable diagnosis of laryn-
geal precursor lesions [64]. Further
correspondence on this issue can be read in the
recent Letters to the Editor of The Laryngoscope
[62, 65]. Importantly, it should be noted the
demographics and management options for
laryngeal dysplasia are changing over time and
vary within countries and institutions [66].
Therefore, it has been proposed that laryngeal
lesions with dysplastic alterations should be
discussed in a multidisciplinary setting to
determine treatment and follow-up strategies
[67]. These discussions are particularly impor-
tant when a new system is proposed (Table 1).
Some pathologists currently grade laryngeal
dysplasias as mild, moderate or severe while
others prefer to use the two-tier system includ-
ing low- and high-grade dysplasia, with the
high-grade entity encompassing moderate and
severe dysplasia and carcinoma in situ. It
remains critical to categorise various laryngeal
epithelial abnormalities according to their
individual risk of progressing to an invasive
neoplasm. Severe dysplasia and carcinoma
in situ (LIN III) and to a lesser extent mild and
moderate dysplasia (LIN I and LIN II) do carry
this risk. On the contrary, laryngeal aberrations
of squamous metaplasia, squamous cell hyper-
plasia, pseudoepitheliomatous hyperplasia and
simple keratosis without atypia lack this
potential. These abnormalities in the surface
epithelium have been erroneously considered
premalignant, but they have a favourable
prognosis and therefore do not warrant fre-
quent follow-up [59]. Severe dysplasia (but not
moderate dysplasia) carries the same high risk
Table 1 Nomenclature for the development of laryngeal dysplasia
Nomenclature Author(s) Year References
Intraepithelial carcinoma Altmann et al. 1952 [1]
Carcinoma in situ Reagan et al. 1953 [9]
Proliferative squamous cell lesions Kleinsasser 1963 [7]
Carcinoma in situ Miller and Batsakis 1974 [10]
Squamous intraepithelial neoplasia (SIN) Friedmann and Osborn 1976 [13]
Dysplasia, carcinoma in situ WHO classification 1978 [11]
Intraepithelial neoplasia of the larynx Crissman and Fu 1986 [42]
Laryngeal intraepithelial neoplasia (LIN) Friedmann and Ferlito 1988 [36]
Squamous intraepithelial lesion (SIL) Gale et al. 2014 [55]
Dysplasia: low-grade, high-grade WHO classification 2017 [44]
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for developing invasive carcinoma as carcinoma
in situ and these entities are therefore grouped
together for clinical purposes.
The use of immunohistochemistry and other
biomarkers to improve and support the histo-
logical assessment and prediction of the pro-
gression of SILs and/or risk for development of
cancer has virtually no practical value. A more
recent study used cytokeratin 19 and concluded
reduced inter- and intra-examiner variability
[68]. This study was however performed on
dysplastic lesions of the upper aerodigestive
tract as a whole and on non-keratinising
epithelia only. Therefore, it is not specific or
particularly valid for laryngeal dysplasia, as
most of laryngeal SILs have keratinising
epithelium. Another immunohistochemical
investigation of laryngeal precancerous lesions
investigated the role of NANOG expression. The
human NANOG protein, encoded by the
NANOG1 gene, is a transcriptional factor that is
involved in the maintenance of pluripotency in
embryonic stem cells. The study showed that
strong NANOG protein expression had a strong
association with risk for development of inva-
sive laryngeal carcinoma [69]. Another most
interesting and promising immunohistochemi-
cal study on precancerous laryngeal lesions
analysed the expression of CTTN and FAK (the
genes CTTN, cortactin, and FAK, focal adhesion
kinase, are both known to induce an aggressive
behaviour in various cancers) in a cohort of 109
patients. The study concluded that both CTTN
and FAK are powerful predictors for risk of
recurrence and development into invasive car-
cinoma and to a degree that is considerably
superior to conventional histological grading
[70]. Recently, the same group also reported a
combined immunohistochemical and molecu-
lar study (real-time PCR) on laryngeal precan-
cerous lesions that is equally interesting. The
investigations concluded that SOX2 gene
amplification (p = 0.046) and SOX2 protein
expression (p\ 0.001) but not the histological
grading (p = 0.432) were significantly associated
with increased risk for laryngeal carcinoma [71].
The use of immunohistochemical identification
of SOX2 may develop into a very practical and
possibly reliable ancillary technique to the his-
tological assessment of laryngeal squamous
intraepithelial lesions. Also imaging examina-
tion techniques have been tested in attempts to
estimate the risks for progression of different
types of laryngeal dysplasia. One study using
secondary analysis of data from meta-analyses
and randomised trials concluded that narrow-
band imaging (NBI) is preferred over conven-
tional white light imaging (WLI) and describes
the need for NBI in the follow-up of patients
with laryngeal dysplasia [72].
Most molecular/genetic studies have been
performed on invasive laryngeal carcinoma,
and often on head and neck squamous cell
carcinomas in general, as well as in relation to
the role of human papillomavirus (HPV) status
(e.g., [73–77]). Only a few molecular/genetic
studies have been performed on SILs. Muta-
tional profiling in laryngeal dysplasia has been
one approach. A study analysed 66 dysplastic
lesions (24 progressing lesions and 42 non-pro-
gressing lesions) and 24 invasive carcinomas
using targeting next-generation sequencing and
revealed non-synchronous mutations in six
different genes (PIK3CA, FGFR3, TP53, LAK3,
MET, FBXW7). Mutations in PIK3CA and FGFR3
were seen in progressing dysplastic lesions and
invasive carcinomas but not in non-progressing
dysplastic lesions. JAK3, MET and FBXW7
showed mutations in non-progressing dysplas-
tic lesions but not in invasive carcinomas or
progressing dysplastic lesions. The authors
conclude that mutational profiling may be of
value in the early detection of patients at risk of
progression [78]. A recent study investigated a
possible association between the expression of
MAGE-A in laryngeal (and oral) leukoplakia and
malignant transformation to squamous cell
carcinoma [79]. MAGE-A, the melanoma-asso-
ciated antigen A, is expressed in laryngeal and
oral squamous cell carcinomas but is com-
pletely absent in healthy mucosal tissues
[79, 80]. In the study by Baran et al. analyses
were performed using both immunohisto-
chemistry and real time RT-PCR. Their cohorts
consisted of 91 oral and laryngeal leukoplakia
lesions that developed into squamous cell car-
cinoma (5-year follow-up), 114 that did not and
40 healthy mucosal samples. There was a sig-
nificant risk of malignant transformation in
leukoplakia lesions with immunohistochemical
2672 Adv Ther (2020) 37:2667–2677
expression of MAGE-A (p\0.001) and also sta-
tistically significant with real-time RT-PCR
(MAGE-A3/6, p = 0.001 and MAGE-A4,
p = 0.002). Interestingly, there was no signifi-
cant association between MAGE-A expression
and the histological grade of dysplasia (low or
high grade). The authors conclude that the
MAGE-A expression profile can be useful in
predicting the risk of malignant transformation
and therefore potentially a valuable ancillary
technique to conventional histopathology [79].
In summary, the essential change between
the 2005 and 2017 WHO classifications is the
attempt to induce a simplification from a four-
to a two-tier system by the unification into
high-grade dysplasia of former moderate dys-
plasia, severe dysplasia and carcinoma in situ.
One major problem is the persisting ambiguity
in distinguishing low-grade dysplasia from
basal/parabasal cell hyperplasia. Furthermore, it
remains to be discussed how the pathologist
should interpret lesions previously classified in
the spectrum of moderate dysplasia. Do they all
really belong to the category of high-grade
dysplasia? Ongoing and additional studies may
help to clarify underlying events that will
increase our understanding and possibly can
facilitate our attempts to obtain an even better
classification. The classification needs to be
easier for the practising general pathologist to
perform and easier for the clinician to interpret.
Both these two objectives are equally important
to provide each patient the best personalised
treatment available for squamous intraepithe-
lial lesions. Integration of molecular and other
biomarkers in future classification schemes
might positively enhance their predictive value.
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